Search research articles
Contact Us
Filters
Showing results (91-100 of 103) with videos related to
Page
of 11
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 1, 1996
Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines
D Machover, E Diaz-Rubio, A de Gramont, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique
|
November 25, 2004
[Clinical practice guidelines: 2004 Standards, Options and Recommendations for the management of patient with adenocarcinoma of the stomach--radiotherapy]
M Ychou, G Gory-Delabaere, P Blanc, et al.
British Journal of Cancer
|
January 11, 2014
Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial
E Samalin, O Bouché, S Thézenas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 16, 2017
Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment
A R Thierry, S El Messaoudi, C Mollevi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 1, 1997
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy
P Rougier, R Bugat, J Y Douillard, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
April 28, 2012
Management of cutaneous adverse events induced by anti-EGFR (epidermal growth factor receptor): a French interdisciplinary therapeutic algorithm
Z Reguiai, J B Bachet, C Bachmeyer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 23, 2015
FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial
M Hebbar, B Chibaudel, T André, et al.
Gastroenterologie Clinique Et Biologique
|
July 23, 1999
[What can be done for digestive cancer in 1999? Recommendations of the French Foundation of Digestive Cancer (1st Part)]
J C Barbare, L Bedenne, O Bouché, et al.
Gastroenterologie Clinique Et Biologique
|
August 3, 1999
[What can be done for patients with digestive cancer in 1999? Guidelines of the French Foundation of Digestive Cancerology (2nd part)]
J C Barbare, L Bedenne, O Bouché, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 19, 2014
FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial
M Hebbar, B Chibaudel, T André, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 103) with videos related to
Sort By:
Page
of 11
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 1, 1996
Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines
D Machover, E Diaz-Rubio, A de Gramont, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique
|
November 25, 2004
[Clinical practice guidelines: 2004 Standards, Options and Recommendations for the management of patient with adenocarcinoma of the stomach--radiotherapy]
M Ychou, G Gory-Delabaere, P Blanc, et al.
British Journal of Cancer
|
January 11, 2014
Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial
E Samalin, O Bouché, S Thézenas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 16, 2017
Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment
A R Thierry, S El Messaoudi, C Mollevi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 1, 1997
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy
P Rougier, R Bugat, J Y Douillard, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
April 28, 2012
Management of cutaneous adverse events induced by anti-EGFR (epidermal growth factor receptor): a French interdisciplinary therapeutic algorithm
Z Reguiai, J B Bachet, C Bachmeyer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 23, 2015
FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial
M Hebbar, B Chibaudel, T André, et al.
Gastroenterologie Clinique Et Biologique
|
July 23, 1999
[What can be done for digestive cancer in 1999? Recommendations of the French Foundation of Digestive Cancer (1st Part)]
J C Barbare, L Bedenne, O Bouché, et al.
Gastroenterologie Clinique Et Biologique
|
August 3, 1999
[What can be done for patients with digestive cancer in 1999? Guidelines of the French Foundation of Digestive Cancerology (2nd part)]
J C Barbare, L Bedenne, O Bouché, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 19, 2014
FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial
M Hebbar, B Chibaudel, T André, et al.
Page
of 11